Boston Scientific (NYSE:BSX) Upgraded at Wall Street Zen

Key Points

• Boston Scientific has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, reflecting growing confidence in the company's performance.
• Multiple analysts have raised their target prices for Boston Scientific, with the average price target now at $120.71 and a consensus rating of "Buy."
• The stock experienced a strong quarterly performance, reporting $5.06 billion in revenue and $0.75 EPS, exceeding analysts' expectations.

Boston Scientific (NYSE:BSX - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also weighed in on the company. Royal Bank Of Canada restated an "outperform" rating and issued a $125.00 target price on shares of Boston Scientific in a research note on Monday, September 29th. Raymond James Financial upped their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Leerink Partners upped their target price on Boston Scientific from $127.00 to $128.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 1st. Needham & Company LLC restated a "buy" rating and issued a $121.00 target price on shares of Boston Scientific in a research note on Wednesday, October 1st. Finally, Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $120.71.

Boston Scientific Stock Performance

Shares of BSX opened at $95.41 on Friday. The stock's 50-day simple moving average is $101.98 and its 200 day simple moving average is $101.87. The stock has a market capitalization of $141.38 billion, a price-to-earnings ratio of 56.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific has a 52-week low of $80.64 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $17,972,457 over the last 90 days. Company insiders own 0.50% of the company's stock.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CHICAGO TRUST Co NA grew its position in Boston Scientific by 5.4% during the 3rd quarter. CHICAGO TRUST Co NA now owns 34,185 shares of the medical equipment provider's stock worth $3,337,000 after acquiring an additional 1,757 shares during the last quarter. Diversified Enterprises LLC grew its position in shares of Boston Scientific by 3.4% in the 3rd quarter. Diversified Enterprises LLC now owns 3,516 shares of the medical equipment provider's stock worth $343,000 after buying an additional 115 shares during the last quarter. Lineweaver Wealth Advisors LLC bought a new stake in shares of Boston Scientific in the 3rd quarter worth approximately $646,000. Tlwm grew its position in shares of Boston Scientific by 6.4% in the 3rd quarter. Tlwm now owns 15,448 shares of the medical equipment provider's stock worth $1,508,000 after buying an additional 928 shares during the last quarter. Finally, Sound Income Strategies LLC grew its position in shares of Boston Scientific by 314.3% in the 3rd quarter. Sound Income Strategies LLC now owns 1,044 shares of the medical equipment provider's stock worth $102,000 after buying an additional 792 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.